Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$49 Mln
P/E Ratio
--
P/B Ratio
0.65
Industry P/E
--
Debt to Equity
0.01
ROE
-0.8 %
ROCE
-74.74 %
Div. Yield
0 %
Book Value
1.89
EPS
-0.74
CFO
$--
EBITDA
$--
Net Profit
$--
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Skye Bioscience, Inc. (SKYE)
| -36.75 | -20.44 | -31.42 | -87.24 | -40.51 | -40.98 | -47.56 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
|
|---|---|
|
Skye Bioscience, Inc. (SKYE)
| 4.01 |
|
S&P Small-Cap 600
| 7.01 |
|
BSE Sensex
| 8.10 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.21 | 9,808.03 | 20.22 | 23.13 | |
| 302.88 | 8,956.09 | 22.08 | 58.42 | |
| 27.39 | 9,559.25 | -- | -28.77 | |
| 105.76 | 10,030.35 | 30.81 | 14.16 |
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a... peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. Address: 11250 El Camino Real, San Diego, CA, United States, 92130 Read more
Executive Chairman, President, CEO & Secretary
Mr. Punit S. Dhillon B.A.
President, CEO, Secretary & Director
Mr. Punit S. Dhillon B.A.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Skye Bioscience, Inc (SKYE) stood at $ 73 Mln as on 31-Dec-24
The share price of Skye Bioscience, Inc (SKYE) is $1.79 (NASDAQ) as of 24-Apr-2025 16:22 EDT. Skye Bioscience, Inc (SKYE) has given a return of -40.51% in the last 3 years.
Skye Bioscience, Inc (SKYE) has a market capitalisation of $ 49 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Skye Bioscience, Inc (SKYE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Skye Bioscience, Inc (SKYE) and enter the required number of quantities and click on buy to purchase the shares of Skye Bioscience, Inc (SKYE).
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. Address: 11250 El Camino Real, San Diego, CA, United States, 92130
The CEO & director of Mr. Punit S. Dhillon B.A.. is Skye Bioscience, Inc (SKYE), and CFO & Sr. VP is Mr. Punit S. Dhillon B.A..
There is no promoter pledging in Skye Bioscience, Inc (SKYE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Skye Bioscience, Inc. (SKYE) | Ratios |
|---|---|
|
Return on equity(%)
|
-80.48
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Skye Bioscience, Inc (SKYE) was $0 Mln.
$0.06
(
